Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571668 | 0.86 | NTRK1 (0.38) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL16171674 | 0.84 | NTRK1 (0.38) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL20952658 | 0.81 | KIT (0.39) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL20438069 | 0.81 | NTRK1 (0.36) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL22381401 | 0.80 | ALDH1A1 (0.43) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL21151016 | 0.80 | HDAC3 (0.35) | — | |
| SCHEMBL22400121 | 0.80 | MEN1 (0.45) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL4751928 | 0.79 | MAPK1 (0.45) | TSHRMEN1MAPK1KMT2ASRC | |
| SCHEMBL23937854 | 0.78 | NTRK1 (0.41) | NTRK1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL22400120 | 0.78 | NTRK1 (0.37) | NTRK1TSHRMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11767336-B2 | Organometallic cluster photoresists for EUV lithography | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | RNGTT, RNMT, DNPEP | NTRK1 3426/4885TSHR 3025/4885MEN1 4033/4885 |
| US-11767336-B2 | Organometallic cluster photoresists for EUV lithography | ETV6, CDV3, RUVBL2 | NTRK1 3663/4885TSHR 4564/4885MEN1 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.